HOME >> BIOLOGY >> NEWS
Newly-discovered class of genes determines and restricts stem cell fate

(Philadelphia, PA) Research on adult stem cells found in the skin hints at a new class of genes, according to a study from investigators at the University of Pennsylvania School of Medicine. These genes dubbed pangenes can both govern a stem cell's fate and put a hold on future differentiation until the time is right. Understanding the molecular control of these genes has implications for therapies that involve tissue regeneration.

The researchers found that Pax3, a gene critical in embryonic development of melanocytes cells that make and store the pigments in the skin and hair is also expressed in adult stem cells in the skin.

"Our findings told us that a recapitulation of an embryonic program is occurring in resident stem cells in adult skin," explains Jon Epstein, MD, Professor of Medicine, Cardiovascular Division. "These few rare stem cells were expressing genes that previously had only been known to be expressed in a developing embryo. That was the first clue that we were on to something new." Epstein and colleagues report their findings in the February 24th issue of Nature.

The scientists found that Pax3 plays dual and somewhat seemingly contradictory roles in adult stem cells: it directs them to become melanocytes, but simultaneously prevents them from differentiating completely. "It gets the show going, but at the same time, prevents the final act," says Epstein. "I call this dual function a "biological capacitor," because Pax3 tells the cell: Get ready to go, but at the same time won't let it proceed."

Pangenes Express Behavioral Qualities of Pan and Peter Pan

Epstein notes that this research is conceptually new since he suggests that a single gene can both tell a cell what it should become and restrict its fate by preventing differentiation. The ability of a single biochemical factor or complex of factors to have this dual role may represent a new general paradigm for developmental and stem
'"/>

Contact: Ed Federico
ed.federico@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
23-Feb-2005


Page: 1 2

Related biology news :

1. Damon Runyon names new class of rising stars in cancer research
2. Pendulum love, science class gender gaps, musical mind mirrors, and unparticle physics
3. New algorithms classify outcomes of nonsmall cell lung cancer patients
4. UCLA molecular biologists convert protein sequences into classical music
5. Double honor recognises world-class science and spin-out success
6. Misclassified for centuries, medicinal leeches found to be 3 distinct species
7. Fighting to keep Darwin in the classroom
8. Funding boost for QUT world-class banana research
9. Protein folding physics, nanohandles, sunscreen for algae and classical quantum weirdness
10. New understanding of COX-1 and COX-2 enzymes could revise classification of pain meds
11. Free access to world-class biological databases for European science thanks to FELICS

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
Cached News: